Replimune (REPL) Accounts Payables (2018 - 2026)
Replimune (REPL) posted Accounts Payables of $6.7 million for Q1 2026, up 18.13% sequentially from $5.6 million in Q4 2025, and down 46.47% YoY from $12.5 million in Q1 2025.
Replimune (REPL) Accounts Payables (2018 - 2026) Analysis & Trends
Replimune has reported Accounts Payables for 9 years, with the latest figure at $6.7 million in Q1 2026.
- Quarterly Accounts Payables fell 46.47% year-over-year to $6.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $6.7 million (down 46.47% YoY) and the FY2026 annual result came in at $6.7 million, down 46.47% from the prior year.
- Accounts Payables advanced to $6.7 million in Q1 2026 per REPL's latest filing, from $5.6 million in the prior quarter.
- Over five years, Accounts Payables peaked at $15.5 million in Q2 2025 and troughed at $864000.0 in Q2 2024.
- A 5-year average of $5.9 million and a median of $4.9 million in 2023 frame the typical range for Accounts Payables.
- The sharpest annual moves came in 2024 and 2025: Accounts Payables sank 82.31% in 2024, then soared 1692.01% in 2025.
- Over 5 years, Accounts Payables stood at $3.6 million in 2022, then advanced by 6.99% to $3.9 million in 2023, then jumped by 84.17% to $7.2 million in 2024, then retreated by 21.44% to $5.6 million in 2025, then increased by 18.13% to $6.7 million in 2026.
- According to Business Quant data, Accounts Payables over the past three periods registered $6.7 million, $5.6 million, and $6.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.52 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 88.42 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 470.30 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.05 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 35.57 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 108.02 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 428.93 Mn |
| 10 | Replimune | 1.24 Bn | 1.24 Bn | - | 6.67 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 6.67 Mn |
| Dec 31, 2025 | 5.65 Mn |
| Sep 30, 2025 | 6.40 Mn |
| Jun 30, 2025 | 15.48 Mn |
| Mar 31, 2025 | 12.46 Mn |
| Dec 31, 2024 | 7.19 Mn |
| Sep 30, 2024 | 8.41 Mn |
| Jun 30, 2024 | 864,000.00 |
| Mar 31, 2024 | 2.58 Mn |
| Dec 31, 2023 | 3.90 Mn |
| Sep 30, 2023 | 4.37 Mn |
| Jun 30, 2023 | 4.88 Mn |
| Mar 31, 2023 | 5.36 Mn |
| Dec 31, 2022 | 3.65 Mn |
| Sep 30, 2022 | 4.00 Mn |
| Jun 30, 2022 | 4.48 Mn |
| Mar 31, 2022 | 3.73 Mn |
| Dec 31, 2021 | 3.92 Mn |
| Sep 30, 2021 | 3.15 Mn |
| Jun 30, 2021 | 2.38 Mn |